Project Brief
A South Korea-based molecular diagnostics company specializing in the development of companion diagnostics (CDx) for targeted cancer therapies. The company’s flagship product is the EGFR Detection Kit, a next-generation PCR based EGFR mutation test built on its proprietary PCR chemistry platform.
Despite growing use of EGFR-targeted therapies in non-small cell lung cancer (NSCLC), many healthcare systems still face challenges with current testing solutions. Existing diagnostics often:
Miss rare or resistance mutations (like exon 20 insertions or C797S)
Take too long to return results, delaying treatment decisions
The kit is designed to detect a broad panel of 8 clinically significant EGFR mutations, including:
Activating mutations
Uncommon but actionable variants
Resistance mutations
Exon 20 insertions
Project Overview
This project aims to evaluate the clinical relevance, usability, and market fit of the EGFR mutation test kit across global markets. The study will explore how experts currently approach EGFR testing in NSCLC, identify key pain points, and assess how this new kit could improve clinical workflows, speed, and mutation coverage.
Advisors Needed
Industry Expert Specialties:
Sales, marketing, or BD professionals in oncology diagnostics (≥10 years)
Experience in commercial strategy, regulatory engagement, or CDx partnerships
Medical Expert Specialties:
Oncologists managing NSCLC (≥10 years of experience)
Onco-pathologists or molecular pathologists involved in EGFR testing (≥10 years)
Geographical Focus Key Regions: Globally
Work Required: Advisors will be provided with a detailed background document on the company and its flagship product, including its features, benefits, and the company’s vision for a new orthodontic treatment journey.
Survey Completion: Experts will provide detailed feedback through a survey consisting of approximately 25-30 multiple-choice and open-ended questions focused on market potential, usability, and clinical impact.
Estimated Time Commitment: ~1 hour